MedPacto, Inc. (235980.KQ)
KRW 4585.0
(-1.4%)
KRW 4585.0
(-1.4%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -28.75 Billion KRW | 22.8% |
| 2022 | -37.24 Billion KRW | -26.43% |
| 2021 | -29.45 Billion KRW | -5.97% |
| 2020 | -27.79 Billion KRW | -109.99% |
| 2019 | -13.23 Billion KRW | -30.27% |
| 2018 | -10.16 Billion KRW | -214.25% |
| 2017 | -3.23 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -5.11 Billion KRW | 47.32% |
| 2024 Q1 | -9.7 Billion KRW | -27.18% |
| 2023 Q4 | -7.63 Billion KRW | -22.7% |
| 2023 FY | -28.75 Billion KRW | 22.8% |
| 2023 Q3 | -6.21 Billion KRW | 19.25% |
| 2023 Q2 | -7.7 Billion KRW | -6.94% |
| 2023 Q1 | -7.2 Billion KRW | 48.55% |
| 2022 Q2 | -7.13 Billion KRW | 29.38% |
| 2022 FY | -37.24 Billion KRW | -26.43% |
| 2022 Q3 | -6.01 Billion KRW | 15.72% |
| 2022 Q4 | -13.99 Billion KRW | -132.83% |
| 2022 Q1 | -10.1 Billion KRW | -51.98% |
| 2021 Q1 | -5.63 Billion KRW | -70432.99% |
| 2021 Q3 | -9.05 Billion KRW | -11.39% |
| 2021 Q2 | -8.12 Billion KRW | -44.29% |
| 2021 Q4 | -6.64 Billion KRW | 26.59% |
| 2021 FY | -29.45 Billion KRW | -5.97% |
| 2020 Q3 | -9.71 Million KRW | 0.0% |
| 2020 FY | -27.79 Billion KRW | -109.99% |
| 2020 Q4 | -7.98 Million KRW | 17.77% |
| 2019 FY | -13.23 Billion KRW | -30.27% |
| 2018 FY | -10.16 Billion KRW | -214.25% |
| 2017 FY | -3.23 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HLB Co., Ltd. | -125.02 Billion KRW | 77.003% |
| iNtRON Biotechnology, Inc. | -3.28 Billion KRW | -775.265% |
| BINEX Co., Ltd. | 1.04 Billion KRW | 2858.621% |
| Bioneer Corporation | 791.75 Million KRW | 3731.448% |
| Anterogen.Co.,Ltd. | -5.07 Billion KRW | -466.673% |
| MEDIPOST Co., Ltd. | -25.13 Billion KRW | -14.41% |
| CrystalGenomics, Inc. | -30.91 Billion KRW | 6.99% |
| Helixmith Co., Ltd | -35.24 Billion KRW | 18.423% |
| Chabiotech Co.,Ltd. | -9.42 Billion KRW | -205.056% |
| Medy-Tox Inc. | 17.32 Billion KRW | 265.983% |
| Peptron, Inc. | -15.6 Billion KRW | -84.274% |
| Amicogen, Inc. | 2.05 Billion KRW | 1498.352% |
| Genexine, Inc. | -41.24 Billion KRW | 30.283% |
| HLB Therapeutics Co.,Ltd. | -8.7 Billion KRW | -230.474% |
| LegoChem Biosciences, Inc. | -80.82 Billion KRW | 64.426% |
| ALTEOGEN Inc. | -9.73 Billion KRW | -195.292% |
| PharmaResearch Co., Ltd. | 100.81 Billion KRW | 128.519% |
| SillaJen, Inc. | -21.34 Billion KRW | -34.696% |
| JETEMA, Co., Ltd. | 2.63 Billion KRW | 1191.725% |
| OliX Pharmaceuticals,Inc | -18.18 Billion KRW | -58.106% |
| Genomictree Inc. | -17.3 Billion KRW | -66.164% |
| D&D Pharmatech | -13.48 Billion KRW | -113.196% |
| EASY BIO,Inc. | 20.63 Billion KRW | 239.362% |
| GI Innovation, Inc. | -55.6 Billion KRW | 48.291% |